MediLink’s B7-H3-targeted antibody-drug conjugate tambotatug pelitecan achieves overall survival and progression-free survival benefits in Chinese patients with relapsed small cell lung cancer.
MediLink’s B7-H3-targeted antibody-drug conjugate tambotatug pelitecan achieves overall survival and progression-free survival benefits in Chinese patients with relapsed small cell lung cancer.